Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 20/20 | 0.83 |
| ▸ | EGFR | P00533 | 1/20 | 0.81 |
| ▸ | INSR | P06213 | 1/20 | 0.81 |
| ▸ | PTGIR | P43119 | 1/20 | 0.81 |
| ▸ | CASP9 | P55211 | 1/20 | 0.81 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.81 |
| ▸ | SOAT2 | O75908 | 3/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.65 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409086 | 1.00 | DGAT1 (0.83) | DGAT1EGFRINSRPTGIRCASP9 | |
| SCHEMBL409876 | 0.94 | DGAT1 (0.84) | DGAT1EGFRINSRPTGIRCASP9 | |
| SCHEMBL409875 | 0.94 | DGAT1 (0.84) | DGAT1EGFRINSRPTGIRCASP9 | |
| SCHEMBL10197467 | 0.93 | DGAT1 (0.71) | DGAT1EGFRINSRPTGIRCASP9 | |
| SCHEMBL408715 | 0.91 | DGAT1 (1.00) | DGAT1EGFRINSRPTGIRCASP9 | |
| SCHEMBL408716 | 0.91 | DGAT1 (1.00) | DGAT1EGFRINSRPTGIRCASP9 | |
| SCHEMBL410357 | 0.90 | DGAT1 (0.79) | DGAT1EGFRINSRPTGIRCASP9 | |
| SCHEMBL410356 | 0.90 | DGAT1 (0.79) | DGAT1EGFRINSRPTGIRCASP9 | |
| SCHEMBL406411 | 0.90 | DGAT1 (1.00) | DGAT1EGFRINSRPTGIRCASP9 | |
| SCHEMBL406410 | 0.90 | DGAT1 (1.00) | DGAT1EGFRINSRPTGIRCASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022057-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | DGAT1 2/4885EGFR 4045/4885INSR 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.